Approval Order StatementApproval to expand the product matrix to include the 2. 25 mm taxus liberte paclitaxel-eluting coronary stent system. This device size will be marketed under the trade name taxus liberte atom paclitaxel-eluting coronary stent system (monorail and over-the-wire delivery systems), and is indicated for improving luminal diameter for the treatment of de novo lesions in native coronary arteries > =2. 25 mm to <= 4. 00 mm in diameter in lesions <= 28 mm in length.